A leading RNAi therapeutics firm.

In sharpened contrast, seven weekly doses in excess of 100 mg/kg were very well tolerated in HA mice; 100 percent of animals survived, and there have been no significant findings in clinical or anatomic pathology examinations toxicologically. Furthermore, single doses as high as 500 mg/kg were very well tolerated in both HA and HB mice. Since ALN-AT3 efficacy toward improved hemostasis is achieved at weekly doses less than 1 mg/kg, these total results support a greater than 100-fold therapeutic index for ALN-AT3 in the hemophilia setting. Alnylam plans to file an investigational new drug software for ALN-AT3 in mid-2013.In this community-based research population of white or black nondiabetic adults, glycated hemoglobin was superior to fasting glucose for assessment of the long-term risk of subsequent cardiovascular disease, especially at values above 6.0 percent. Such prognostic data may enhance the evidence supporting the usage of glycated hemoglobin as a diagnostic test for diabetes.. Abraxis Bioscience first-one fourth ABRAXANE revenue raises to $87.9 million Abraxis BioScience, Inc. , a integrated biotechnology company fully, reported unaudited financial results for the first quarter finished March 31 today, 2010.8 million compared with $72.6 million for the first quarter of 2009.9 million weighed against $70.1 million for the first quarter of 2009.